A breakthrough in medical technology could soon turn a simple sound into a life-saving diagnostic tool. Australian startup Sonorus is developing an AI-powered algorithm designed to identify signs of rheumatic heart disease (RHD) by analyzing heart sounds—potentially detecting the condition long before traditional methods can.
The Silent Threat: Understanding RHD
To understand the importance of this technology, one must look at the devastating impact of rheumatic heart disease. RHD is caused by inflammation following a Strep A infection, which eventually leads to permanent damage to the heart valves.
The scale of the problem is significant:
– Global Impact: Approximately 55 million people are affected worldwide.
– Mortality: The disease claims roughly 360,000 lives every year.
– Inequality: It disproportionately affects lower socioeconomic communities, including Indigenous populations in Australia and the U.S., as well as regions across Africa, the Middle East, and Southeast Asia.
The tragedy of RHD lies in its progression. While it can be managed early with inexpensive penicillin, late-stage detection often requires complex open-heart surgery. Currently, most patients do not seek help until they experience severe symptoms like chest pain or shortness of breath, by which time the damage is often irreversible.
Bridging the Gap: AI vs. Traditional Diagnostics
The current “gold standard” for diagnosing heart issues is the echocardiogram (ultrasound). While highly accurate, echocardiograms have two major drawbacks that Sonorus aims to address: cost and accessibility.
An ultrasound machine can cost between $10,000 and $20,000, and requires highly trained specialists to operate. This makes mass screening in remote or underserved areas nearly impossible.
Sonorus offers a different approach:
* Early Detection: While doctors use stethoscopes to hear damage that is already present, Sonorus’ AI looks for “precursory markers”—subtle acoustic patterns invisible to the human ear—that signal trouble is coming.
* Portability and Affordability: The startup aims to create a device that could cost under $700 (AU$1,000), making it a viable tool for mass screening.
* Triage, Not Replacement: The goal is not to replace doctors, but to act as a high-efficiency screening tool. By identifying high-risk individuals early, the AI allows medical professionals to focus their expertise on the cases that need it most.
From a Two-Bedroom Apartment to Global Ambition
The journey of Sonorus began in 2022, born from a collaboration between CEO Dr. Julie Dao, a cardiovascular health PhD, and CTO Leah Martínez, an engineer. What started as a “crazy idea” worked on in a small apartment has evolved into a fully functioning prototype supported by academic accelerators like Monash University.
The company’s biggest challenge is currently data acquisition. In the world of artificial intelligence, an algorithm is only as effective as the data used to train it. To ensure clinical viability, Sonorus is working to build the world’s largest dataset of high-quality, clinically verified heart sounds.
Community-Centric Innovation
Crucially, Sonorus is not just building technology in a vacuum. Recognizing that healthcare is built on trust, the founders are consulting directly with the communities they aim to serve, such as Indigenous Australian and Pacific Islander groups.
By involving these communities in the development process, Sonorus aims to ensure their tools are culturally sensitive, easy to use, and—most importantly—trusted by the people who need them most.
The Future of Cardiovascular Care
While the current focus is strictly on RHD, the potential for this technology is much broader. Because AI algorithms are highly scalable, Sonorus envisions a future where a single, simple acoustic test could screen for a wide variety of valvular diseases.
“We’re starting with rheumatic heart disease… and from there, we want to move to other valvular diseases as well.”
Conclusion
By leveraging AI to “hear” what humans cannot, Sonorus is moving heart disease diagnosis from reactive surgery toward proactive, affordable prevention. If successful, this technology could close the gap in global healthcare equity, catching silent killers before they strike.
